HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $21.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley decreased their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Price Performance

NASDAQ PDSB opened at $1.23 on Friday. PDS Biotechnology has a 52-week low of $1.13 and a 52-week high of $6.00. The firm’s 50 day moving average price is $1.49 and its 200-day moving average price is $2.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The company has a market cap of $46.98 million, a PE ratio of -1.06 and a beta of 1.68.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of PDS Biotechnology during the fourth quarter worth $26,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter worth $58,000. Marshall Wace LLP lifted its stake in shares of PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after buying an additional 10,837 shares during the period. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter worth $89,000. Finally, Two Sigma Investments LP lifted its stake in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after buying an additional 48,132 shares during the period. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.